Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.59 |
| ▸ | HTR2A | P28223 | 16/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.59 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838748 | 0.89 | SLC6A4 (0.75) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL7568917 | 0.84 | HTR2A (0.55) | SLC6A4HTR2AKCNH2EPAS1SLC6A2 | |
| SCHEMBL5836407 | 0.77 | HTR2A (0.67) | SLC6A4HTR2AKCNH2EPAS1 | |
| SCHEMBL5836402 | 0.76 | HTR2A (0.48) | SLC6A4HTR2AKCNH2EPAS1SOS1 | |
| SCHEMBL5836991 | 0.75 | HTR2A (0.80) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL5838755 | 0.74 | HTR2A (0.73) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL2629466 | 0.70 | HTR7 (0.46) | — | |
| SCHEMBL5837060 | 0.69 | SLC6A4 (0.67) | SLC6A4HTR2AKCNH2EPAS1SLC6A2 | |
| SCHEMBL10834476 | 0.68 | HRH3 (0.49) | SLC6A4HTR2AKCNH2EPAS1HRH3 | |
| SCHEMBL6153137 | 0.68 | HTR2A (0.67) | SLC6A4HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020147206-A1 | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | PFIZER INC. | 2002-10-10 | — | — | US | claimed |
| US-6677378-B2 | AS SEROTONIN, NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIBITORS, FOR THERAPY OF CENTRAL NERVOUS SYSTEM AND OTHER DISORDERS | PFIZER INC. | 2004-01-13 | — | — | US | disclosed |
| US-20020143003-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC. | 2002-10-03 | — | — | US | disclosed |
| US-6436938-B1 | ADMINISTERING A SIGMA RECEPTOR LIGAND IN COMBINATION WITH AN ANTIDEPRESSANT AGENT; ESPECIALLY FOR REFRACTORY DEPRESSION | PFIZER INC. | 2002-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147206-A1 | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | PMP22, GAP43, SLC6A2 | SLC6A4 4/4885HTR2A 108/4885KCNH2 368/4885 |
| US-20020143003-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | SLC6A2, SLC6A4, SLC6A3 | SLC6A4 2/4885HTR2A 24/4885KCNH2 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.